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Abstract  
Objective 
RCTs have been criticised for lacking external validity. We assessed whether a trial in people 
with type I diabetes mellitus (T1DM) mirrored the wider population, and applied sample-
weighting methods to assess the impact of differences on our trial's findings. 
Study design and setting 
The REPOSE trial was nested within a large UK cohort capturing demographic, clinical and 
quality of life (QoL) data for people with T1DM undergoing structured diabetes-specific 
education. We firstly assessed whether our RCT participants were comparable to this cohort 
using propensity score modelling. Following this we re-weighted the trial population to 
better match the wider cohort and re-estimated the treatment effect. 
Results 
Trial participants differed from the cohort in regards to sex, weight, HbA1c and also QoL and 
satisfaction with current treatment. Nevertheless, the treatment effects derived from 
alternative model weightings were similar to that of the original RCT. 
Conclusions 
Our RCT participants differed in composition to the wider population but the original 
findings were unaffected by sampling adjustments. We encourage investigators take steps 
to address criticisms of generalisability, but doing so is problematic: external data, even if 
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The randomised controlled trial (RCT) is considered the gold standard for assessing health 
interventions. RCTs nevertheless have drawn a number of criticisms, one of which is their 
generalisability[1]. Trial participants are assumed to be a random sample of a wider target 
population in order to make valid inference but, as several authors have previously claimed, 
this is an optimistic (and probably unrealistic) assumption[1,2]. RCTs recruit volunteers who 
consent to be studied; those who participate may differ in some important characteristics to 
those who do not, a phenomenon referred to as volunteer bias[3]. Furthermore, the 
institutions involved in recruiting may themselves not be a representative of the wider 
population[4,5]. Therefore, whilst the randomised groups within the trial are comparable to 
each other (“internally valid”), inferences drawn from such studies are questionable if those 
who enter an RCT are in some way different to those who do not (“externally invalid”)[6,7].  
An important caveat is that even where selected and non-selected participants differ in their 
characteristics , the treatment comparison remains unbiased unless the reasons for non-
uptake are also associated with the treatment effect (i.e. effect modifiers)[8,9].  These 
conditions are seldom known for any given situation: trials generally collect very limited 
data on individuals who do not participate [10,11], and studies typically have little power to 
detect differential effects across patient characteristics[12]. Whilst there is compelling 
meta-epidemiological evidence that RCT cohorts differ from wider patient populations[13–
23], and the potential for bias in the treatment effect has been demonstrated[24,25], less is 
known as to whether this impacts on the overall estimated treatment difference. 
Proponents of RCTs claim that randomisation, even on selected participants, is less biased 
than alternative study designs[26]. Nevertheless, the credibility and uptake of a trial’s 
findings are at least questionable if its participants do not mirror those that a healthcare 
professional sees in routine practice. 
Methodology to adjust for non-random sampling are commonly used when analysing 
surveys[27,28] but seldom employed for RCTs[8,29]. We describe a cohort of people with 
type 1 diabetes mellitus (T1DM), a subset of whom entered into a RCT. This allows us to 
explore whether trial participants were representative and, if not, whether this impacted on 
the trial findings. We also describe some practicalities and limitations of methods which can 
be used to assess these. 
 
2 Methods 
2.1 Case study 
2.1.1 The REPOSE trial 
The REPOSE (Relative Effectiveness of Pumps over MDI and Structured Education) trial was a 
randomised trial evaluating two modalities for delivering insulin to people with type 1 
diabetes (T1DM)[30]. Participants were randomised to continuous subcutaneous insulin 
infusion (CSII, also known as insulin pump) or to the conventional multiple daily injections 
(MDI). As part of the trial, all participants also attended a DAFNE (Dose Adjustment for 
Normal Eating) diabetes educational course [31] shortly after randomisation.  
The REPOSE trial recruited participants from 8 UK centres between March 2012 and June 
2013. The primary endpoint was the reduction in HbA1c at 2 years among the subset of 
participants with HbA1c ≥58mmol/mol (7.5%) at baseline, and demonstrated only marginal 
clinical benefit of CSII (mean difference 2.7mmol/mol (0.24%), 95% confidence interval -0.5 
to 5.8mmol/mol, p=0.10).   
 
2.1.2 The DAFNE UK database 
The DAFNE programme is a five-day course which aims to improve self-management of 
T1DM by equipping people with the skills necessary to review and respond to results of 
blood glucose monitoring, estimate their carbohydrate intake and administer accurate 
insulin doses dependent on a range of variables through adjustment of insulin on a meal by 
meal basis [31]. The UK National Institute for Health and Care Excellence recommends 
people with T1DM undergo a structured educational programme and specifically endorse 
DAFNE[32]. In 2008, a nationwide DAFNE database was set up to collect details of 
individuals who had undergone DAFNE training in the UK and consented to their data being 
used for research purposes[33]. 72 centres collected pre-course demographic and diabetes-
specific characteristics, ten of which were designated research sites in which individuals 
were given the option to consent to additional data collection including insulin dosage, 
laboratory measures and health utility and quality of life (QoL) inventories. A summary of 
the data collected is presented in box 1. 
 
2.2 Comparison of cohort and nested RCT populations  
We used the DAFNE database to identify people undergoing DAFNE training as part of the 
REPOSE trial and compared these against people from the wider T1DM population who 
partook in the DAFNE course and who would have been eligible for REPOSE. We compared 
the characteristics of the REPOSE trial participants against three subgroups who had 
attended DAFNE training: 
1. Those undertaking DAFNE at the same eight centres during the REPOSE RCT 
recruitment period but were not recruited into the trial.  
2. Those undertaking DAFNE in any of the 72 centres between December 2008 and 
March 2015.  
3. Those undertaking DAFNE in the 10 DAFNE research centres and consenting to 
additional data collection between December 2008 and March 2015.  
The three comparisons assess different facets of generalisability. The rationale for 
comparison 1 is to assess whether any participant characteristics are associated with 
participation in the REPOSE RCT and which therefore may indicate a selection effect in the 
recruitment process. Comparisons 2 and 3 assess how well the trial population represents 
the wider cohort of people with T1DM that undergo DAFNE training and any differences 
here may also reflect temporal effects or case-mix differences between recruiting and non-
recruiting centres. Comparison 2 includes more individuals but is limited to less detailed 
data.   
 
2.3 Statistical methods 
2.3.1 Assessing (dis)similarity between the RCT and cohort populations 
The dissimilarity between the RCT and cohort was assessed using a logistic regression model 
for which the probability of an individual i entering the RCT is dependent on measurable 
characteristics x1i, …,xk  
  ()1 − () =  +  + ⋯ +  
Where pi(x) denotes their predicted probability of inclusion. In the context of assessing and 
adjust for differences between two populations, this probability is referred to as their 
propensity score. Several (related) measures of dissimilarity of RCT and non-RCT participants 
have been proposed including the c-statistic, the Somer’s D coefficient of concordance, the 
standardised mean difference and the Tipton index[8,9,34]. 
 
2.3.2 Re-weighted analysis using the propensity score  
The similarity of the RCT and cohort characteristics was modelled using a two-stage 
approach based on propensity score reweighting[35]. In the first stage, the aforementioned 
logistic regression model was used to model the probability that an individual undergoing a 
DAFNE educational course would also partake in the RCT, using their characteristics at the 
time of the course as explanatory covariates. The second stage repeats the efficacy analysis 
but with different weights allocated to the observations. More specifically, each individual’s 
contribution to the analysis was up-weighted or down-weighted dependent on their value 
of pi(x). Used in this way, propensity scores give more weight to individuals whose 
characteristics are underrepresented in the RCT compared with the wider cohort, therefore 
producing an unbiased estimate of the population average treatment effect (PATE) – 
assuming the regression model is correct. We will return to the development of the model, 
and to this assumption in particular, in the next section.  
Several approaches have been suggested for this reweighting[8,9,36–39], but here we limit 
our analysis to two common methods. The first method stratifies the entire population 
(both randomised and non-randomised) into a small number of equally sized subgroups 
based on their fitted value pi(x). A common choice is to split based on population quintiles 
[40], and this is the approach taken here. Next, the treatment effect is calculated within 
each subgroup among the trial participants. Finally, the overall treatment effect is calculated 
as the simple average of the subgroups. Although each of the five subgroup estimates are 
weighted equally, the trial population has now been reweighted - unless its composition 
matches that of the entire population (i.e. 20% of the trial population are in each subgroup), 
more weight is given to subgroups with fewer trial participants and vice versa. Further 
details, including model assumptions and diagnostic checks, are provided by 
O’Muircheartaigh & Hedges [9]. 
 
The second approach directly weights each individual inversely to their probability of 
inclusion, thereby giving more weight to individuals who are under-represented on the basis 
of their characteristics. The weights are standardised to ensure they sum to the total sample 
size:  
 =  × (/)    
Where  
 = 1()  
and 
 =   ()
 ∈  !"
 
 
The RCT is then re-analysed with these weights applied. The second approach has the 
advantage of not having to arbitrarily divide the trial population into subgroups. However, 
its findings may become unstable where weights are very large or very small – in particular, 
very low probabilities lead to overly influential individual data points. A heuristic but 
effective method to mitigate is to truncate the lowest and highest weights [41]; in this 







2.3.3 Derivation of the propensity score model   
The logistic regression model was built sequentially, starting with the most readily available 
data. Firstly, demographic and routinely collected diabetes characteristics were entered into 
the model. Five variables (age, sex, baseline HbA1c, any previous severe hypoglycaemic 
episode and time since diagnosis) were included in all models, irrespective of statistical 
significance; otherwise, those demonstrating significance at the 0.10 statistical significance 
level were retained. Covariates entered in the next phase comprised laboratory values and 
vital signs whose impact on inclusion were considered less direct; those associated with a 
significant improvement in the model log-likelihood were retained. The model was then re-
assessed for covariates which could be removed: in particular, covariates containing missing 
data were replaced with other related variables to assess whether a similar fit could be 
achieved using the Akaike Information Criterion (AIC). Finally, the model produced was 
compared with those produced by backwards and forwards stepwise regression, with 
additional investigations made where covariates differed. Continuous covariates were 
assessed for non-linearity using fractional polynomial models of 2 and 3 degrees of 
freedom[42] and model improvement was assessed by the likelihood ratio test. The 
propensity score model was reviewed and approved by the trial’s chief investigator prior to 
any re-weighted efficacy analysis being undertaken. 
 
2.3.4 Model Assessment 
Three types of model assessments were undertaken. Firstly, the  stability and goodness of fit 
of the propensity model were assessed by bootstrap methods and the Hosmer-Lemeshow 
test respectively[43]. Second, the residual imbalance following each reweighting method 
described in 2.3.2 was assessed graphically by distributional plots and by the Somer’s D 
statistic[44,45]. Finally, the stability of the reweighted treatment effect was assessed by re-
fitting the propensity model with each covariate sequentially left out and also by bootstrap 
methods as above: in both cases, the re-weighted treatment effect was estimated on the 
modified propensity model and compared with the original re-weighted estimate. The Stata 
code used to undertake these is provided in Appendix 2. 
 
3 Results  
3.1 Participant flow 
267 people were randomised into REPOSE. After excluding participants who were known to 
be ineligible for REPOSE a total of 22020 DAFNE records were available, 2961 of whom were 
from DAFNE research centres and 339 attended one of the eight REPOSE centres during the 
recruitment period (Figure 1). The characteristics of these and the RCT participants are 
summarised in table 1. Although data completeness was generally high, there were 
considerable missing data for laboratory parameters and QoL, which is described in more 
detail below. These were combined with the 267 RCT participants to create the propensity 
score models used to re-weight the RCT population.  
As previously noted, the primary outcome was HbA1c change amongst participants with a 
baseline HbA1c ≥7.5% (58mmol/mol). The reweighted analysis was undertaken on the 224 
participants meeting this criteria and who had 24 month outcome data.  
 
3.2 Comparisons between RCT and cohort participants 
 
3.2.1 Comparison with non-recruited individuals from the same centres and during the 
recruitment period   
RCT participants were slightly older, had greater weight and BMI, and had been living with 
T1DM longer compared to non-randomised individuals attending the recruiting centres 
during recruitment. The randomised individuals also comprised proportionately fewer 
females and fewer individuals with a prior severe hypoglycaemic episode (table 1). These 
characteristics were used to derive the first propensity model. Weight was used in 
preference to BMI as this gave a better model fit (in this and other comparisons). The 
relationship with disease duration and study entry was non-linear with the probability of 
entry highest among individuals between 25-30 years post-diagnosis. Only two of the six 
covariates (weight and years with T1DM) were statistically significant in the multivariable 
propensity score model, but nevertheless there was modest dissimilarity between RCT and 
cohort individuals (table 2).  
3.2.2 Comparison with non-recruited individuals from all centres  
Compared to the entire cohort, RCT participants were similar in terms of age and years since 
T1DM diagnosis but otherwise yielded findings and indices of dissimilarity comparable to 
those seen in the previous model.  
 
3.2.3 Comparison with non-recruited individuals from research centres  
The final models incorporated additional factors collected in the research centres only. The 
two QoL inventories (DSQoL and SF-12) were collected only up to 2012 in the cohort, and 
many laboratory parameters also contained missing data. To deal with this, two models 
were fitted: health utility, QoL and laboratory data were omitted from the first and added to 
the second, with the likelihood ratio testing their importance.  
Both models showed greater separation than previous models (table 2). RCT participation 
was lower among nulliparous females than females with a previous pregnancy and males, 
and presence of retinopathy was positively associated with study entry. Adding QoL and 
laboratory data substantially improved the model (likelihood ratio test p<0.0001 among 
those with data). The two SF-12 QoL measures (physical and mental health) were both 
highly correlated with EQ-5D health utility: SF-12 was preferred on the basis of lower AIC. 
Both physical and mental health components were higher among RCT participants, though 
mental health was non-linearly associated with RCT inclusion and was highest among 
individuals scoring between 40-60 which corresponds to a +/-1 standard deviation of the 
population average[46]. Two of the diabetes specific QoL domains were significantly 
associated with RCT inclusion: RCT participants had tighter treatment goals and greater 
satisfaction with current treatment compared to non- participants. Of the laboratory 
parameters, LDL cholesterol and total cholesterol were higher among RCT participants. The 
two were heavily correlated, and total cholesterol alone was retained as this had far less – 
although still substantial- missing data.  
 
3.3 Re-analysis of the RCT based on propensity score weights  
The methods performed similarly in terms of reducing the residual imbalance between the 
RCT and cohort (see appendix 1 for diagnostic plots) and all three methods were used to re-
weight the treatment effect. The ensuing point estimates varied between 1.0 to 2.8 
mmol/mol (0.09% to 0.26%) with the greatest reduction when reweighting against the 
detailed research cohort individuals. These estimates were in keeping with the 2.4 
mmol/mol (0.22%) difference estimated on complete cases in the original RCT and the 5.5 
mmol/mol (0.5%) defined as the clinically relevant difference in the sample size calculation. 
All 95% confidence intervals overlapped zero, with notably wider confidence intervals for 
the stratified method (figure 2).  
 
3.4 Sensitivity analyses 
In order to assess the sensitivity of the analyses to the propensity model adjustment, 
alternative models were fitted to the comparison within research centres using the 
stratified model, since these were most likely to be affected due to overfitting and small 
strata sizes respectively.  The effect of removing, substituting or adding covariates on the 
effect sizes are shown graphically in figure 3. Although no material differences were evident, 
alternative adjustments generally led to lower effect sizes; in particular omitting total 




We re-analysed a randomised trial conducted in people with type I diabetes mellitus to 
better match the characteristics of the wider population. We had access to a large external 
database containing extensive data for individuals who did not participate in the RCT, thus 
allowing us to explore participant characteristics that are not routinely collected in the 
general population. Although RCT participants differed in some ways from those in the 
external cohort, the original RCT findings were broadly in keeping with the effect sizes 
derived from re-weighting the RCT population.  
 
4.2 Strengths and limitations 
4.2.1 Strengths and limitation of the methodology 
The methods described here need external data containing factors that affect both study 
enrolment and treatment response. This is likely to be the exception rather than the rule; 
even where such data exist the model building will inevitably fail to explain all the subtleties 
which affect inclusion into a trial. In addition, RCTs generally employ extensive ongoing data 
cleaning and would be therefore expected to be of a higher standard than data collected as 
routine practice. Differences between the RCT and wider populations may therefore arise 
due to differences in the data collection processes [47,48]. Most importantly however, 
these methods do not assess the fidelity of the intervention, the baseline standard of care 
and the transferability of the outcome(s) assessed, which are largely non-measurable 
entities. We therefore take the more pragmatic approach noted by O’Muircheartaigh & 
Hedges that a partial reduction in the mismatch between trial and target populations is 
better than no adjustment at all [9].   
 
 
4.2.2 Strengths and limitation of the case study 
A strength of this study is the extensive data collected for the reference population. 
Previous research has shown that some people volunteer for an RCT with the perception it 
may improve their treatment[49,50]: here, a person that considers CSII is willing to (and 
hopeful of) changing how they manage their diabetes. The inclusion of QoL and (in 
particular) DSQoL treatment satisfaction inventories went some way to quantifying this for 
participants in the research database. Nevertheless, analytical methods cannot fully 
incorporate the underlying subtleties of why, for example, younger people were less 
represented. 
A limitation is that entry to the DAFNE research cohort was itself voluntary thereby raising 
possible volunteer bias, although the overall consent rate was over 80%[33]. A further 
limitation is that some DAFNE participants would inevitably have been ineligible for the RCT 
for reasons that were not captured by the database. Had this exclusion criteria been applied 
more fully to the DAFNE cohort we would almost certainly have found it more comparable 
to the trial population, but also less comparable to the wider population who may still be 
candidates for the intervention irrespective of the RCT inclusion criteria. The missing data, 
whilst not substantial, is another limitation which we have not addressed in this analysis. 
Despite these limitations, the DAFNE cohort may still represent a “best case” of external 
data. The database was set up for research activities and is likely to be more extensive and 
of better quality than that which is generally available on non-recruited individuals. The 
“core” data collected at DAFNE sites is comparable to that which would be available 
routinely in clinic, and the differences between RCT and cohort were modest on these 
characteristics. By having access to a large cohort containing quality of life, diabetic 
complications and treatment goals/satisfaction we were able to better discriminate those in 
the RCT from those who were not. Although our reference data is undoubtedly a strength of 
the current research project, this is unlikely to be available to other researchers wanting to 
recalibrate their own findings to the wider population.  
Finally, the specific factors associated with uptake will likely differ across interventions, 
settings, and trials. One feature of T1DM is the emphasis on self-management, which does 
not apply (or apply as strongly) to all conditions. The REPOSE trial also had relatively broad 
inclusion criteria and people were screened routinely rather than selectively with high 
uptake among those eligible. We do not advocate any attempt to extrapolate our 
relationships for trial inclusion outside of this study.  
 
4.3 Other literature 
Several reviews have shown RCTs to be non-random subsets of general patient populations 
(sometimes by design) with findings including the under-representation of older aged 
patients in trials of cancer [13], osteoarthritis[14] and lower back pain[18]; concomitant 
chronic morbidity in trials of coronary heart disease[17]; smoking habits and motivation in 
smoking cessation[19]; lung function in asthma[16]; unemployment and lower educational 
qualification in drug abuse[22]; and both low and high disease severity in pharmacological 
and psychotherapeutic depression trials [21]. Whilst considerations and adjustments for 
non-random sampling are commonplace in electoral polls and market research [27,28], 
equivalent developments for RCTs are rarely quantified[29] and have only recently received 
serious attention. Those which have done are often limited to basic demographic data in the 
general population [51–54], and the relatively small attenuations to the revised effect size 
may be because (non-)recruitment was not adequately characterised by these reasons 
alone. 
A recent attempt to address these issues at the design stage is the PRECIS-2 tool [55,56], 
which incorporates the restrictiveness of exclusion criteria among its criteria. Similarly, the 
Innovative Medicines Initiative (IMI) described considerations for obtaining “real-world 
evidence” from RCTs which encompassed criteria for site selection and patient inclusion 
[5,10,57] – specifically, to make these more broad .   Raymond [58] further advocated RCTs 
should be embedded within clinical care in order to evaluate standard practices on a larger 
scale.  Nevertheless, even the most pragmatic and inclusive trials are reliant on the 
willingness of individuals to participate and therefore subject to volunteer bias[8,59]. 
Under-representation is therefore unlikely to be addressed by design considerations alone.  
This raises the final, fundamental question regarding how the wider world itself is to be 
characterised. Some authors advocate RCTs nested within cohorts (akin to REPOSE) [60,61], 
although this requires the cohort also contains a random subsample of the population being 
studied. Makady et al[62] reported a literature review and stakeholder interviews to 
attempt to reach consensus on what constitutes “real world data”; whilst non-RCT settings 
were unsurprisingly favoured, there was inconsistency among those interviewed on which 
sources (e.g. general practice data, disease specific registries, claim databases) 
appropriately represent the wider population. The quality of such data is a further concern 
with high levels of miscoding, misclassification and misdiagnosis reported for patients with 
diabetes in routinely collected data across several western countries [63–65]. The impact of 
this is difficult to quantify, but there appears inherent inaccuracy in the characterisation 
(and indeed identification) of the wider disease populations.   
 
4.4 Recommendations 
Whilst we encourage researchers to compare their data against a reference population, 
there are barriers to doing so. Obtaining reference data is often difficult, increases the trial 
cost and may lead to unwelcome findings.  Investigating representativeness is necessarily a 
part-exploratory analysis, and an investigator faced with inconsistent findings from 
competing models will be conflicted as to how to report these if the validity of the RCT is 
called into question. Lastly, whilst non-overlap (e.g. a c-statistic of 0.7) suggests a non-
random RCT sample, the converse is not necessarily true; a c-statistic of 0.5 may arise 
because the RCT is truly a random (and therefore unpredictable) sample, but may also arise 
because the model is incomplete. All in all, it is easier not to look. 
We nevertheless encourage more consideration be given to the generalisation of RCTs, the 
simple reason being that RCT evidence may be downplayed (or even overlooked) because it 
appears distant from a readers own practice and experience[66,67]. A sensitivity analysis 
that re-weights the findings to the wider population (however basic) may help bridge this 
gap. Such analyses will ideally be planned in advance as far as possible and consider the 
sample size implications of the modelling at the design stage [68,69]  
5 Conclusions 
We found our RCT differed from the wider population but nevertheless gave the same 
results on sampling reweighting.  We argue that clinical investigators and statisticians 
should apply methods such as these more often. There is an increasing belief that RCTs and 
real-world evidence are divergent, and prospectively planned analyses that compare RCT 
participants against an external population can help build confidence in its findings. 
Obtaining and modelling external data are not straightforward, but we believe that any 
step, however incomplete, will better align RCTs to routine practice.  
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Box 1 Data items collected for the REPOSE RCT and the DAFNE database 
Demographic information:  
Age, sex, ethnicity, weight, BMI, smoking status*, previous pregnancy* 
Diabetes characteristics:  
Years since diagnosis, HbA1c, previous severe hypoglycaemic episode, previous DKA, 
diabetic complications*, years since last reported complication*, insulin dose* 
Laboratory and vital signs:  
Creatinine*, lipids*, blood pressure* 
Quality of life: 
Health utility (EQ-5D*), generic QoL (SF-12+), Diabetes Specific QoL (DSQoL)+ 
 
* Information collected in DAFNE research centres and RCT only. 
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Table 1 Baseline characteristics of RCT participants and the external cohort 
     
RCT (N=267) 







 Age (years) 41 [28,50] 39 [27,51] 39 [28,49] 40 [28,51] 
Missing 0 0 0 26 (0.1%) 
 Sex     
Male 160 (59.9%) 174 (51.3%) 1560 (52.7%) 10832 (49.2%) 
Female 107 (40.1%) 165 (48.7%) 1397 (47.2%) 11097 (50.4%) 
Missing 0 0 4 (0.1%) 91 (0.4%) 
Previous pregnancy (in 
females) * 
    Yes 48 (44.9%) - 411 (29.4%)  
No 56 (52.3%) - 941 (67.2%)  
Missing 3 (2.8%) - 48 (3.4%)  
 Ethnicity     
White British 244 (91.4%) 317 (93.5%) 2687 (90.7%) 20083 (91.2%) 
Other white 8 (3.0%) 13 (3.8%) 214 (7.2%) 1331 (6.0%) 
Other non-white 7 (2.6%) 7 (2.1%) 27 (0.9%) 294 (1.3%) 
Missing/prefer not to say 8 (3.0%) 2 (0.6%) 33 (1.1%) 312 (1.4%) 
 Weight (Kg) 80 [68,91] 75 [64,86] 76 [65,87] 76 [66,87] 
Missing 0 14 (4.1%) 93 (3.1%) 1064 (4.8%) 
BMI (Kg/m2) 27 [24,30] 25 [23,28] 26 [23,29] 26 [23,29] 
Missing 0 25 (7.4%) 190 (6.4%) 1782 (8.1%) 
     
Smoking status 
 Smoker 53 (19.9%) 26 (7.7%) 570 (19.3%) 570 (2.6%) 
Ex-smoker 69 (25.8%) 32 (9.4%) 735 (24.8%) 735 (3.3%) 
Never smoker 145 (54.3%) 63 (18.6%) 1616 (54.6%) 1616 (7.3%) 
Missing 0 (0.0%) 218 (64.3%) 40 (1.4%) 19099 (86.7%) 
 Diabetes characteristics and 
complications 
 Years since diagnosis 16 [8,27] 13 [5,23] 14 [5,25] 15 [7,26] 
Missing 0 4 (1.2%) 22 (0.7%) 424 (1.9%) 
     
     
Any previous severe 
hypoglycaemic episode 30 (11.2%) 47 (13.9%) 637 (21.5%) 4583 (20.8%) 
Missing 0 0 0 0 
Any previous DKA 20 (7.5%) 27 (8.0%) 226 (7.6%) 1593 (7.2%) 
Missing 0 30 (8.8%) 203 (6.9%) 1413 (6.4%) 
     
Daily insulin dose (IU/Kg 
weight) * 0.69 [0.53,0.89] - 0.66 [0.50,0.85] - 
Missing 0 - 197 (6.7%) - 
     
Diabetic complications      
Any complication * 148 (55.4%) - 1137 (38.4%) - 
Neuropathy * 19 (7.1%) - 145 (4.9%) - 
Retinopathy * 115 (43.1%) - 690 (23.3%) - 
Other complication * 101 (37.8%) - 818 (27.6%) - 
 Laboratory measures 
 HbA1c (mmol/mol) * 72 [65,85] 72 [60,81] 70 [60,83] 70 [61,81] 
Missing 0 18 (5.3%) 146 (4.9%) 1988 (9.0%) 
Creatinine(umol/L) * 73 [64,86] - 74 [65,85] - 
Missing 4 (1.5%) - 302 (10.2%) - 
Cholesterol (mmol/mol) * 4.90 [4.30,5.60] - 4.60 [4.00,5.20] - 
Missing 1 (0.4%) - 274 (9.3%) - 
Triglycerides(mmol/L) * 1.10 [0.80,1.60] - 1.00 [0.70,1.50] - 
Missing 0 - 429 (14.5%) - 
     
Generic QoL and health utility      
SF-12 Physical composite QoL* 53.1 [48.3,56.7] - 52.7 [45.3,56.1] - 
Missing 10 (3.7%) - 582 (19.7%) - 
SF-12 Mental composite QoL* 49.4 [42.0,54.4] - 48.9 [38.7,55.0] - 
Missing 10 (3.7%) - 582 (19.7%) - 
EQ-5D health utility * 0.848 [0.760,1.000] - 1.000 [0.779,1.000] - 
Missing 4 (1.5%) - 168 (5.7%) - 
 
 
Diabetes specific QoL  
 Treatment goals* 74.0 [68.0,82.0] - 78.0 [70.0,84.0] - 
Missing 4 (1.5%) - 561 (18.9%) - 
Treatment satisfaction * 62.0 [48.9,72.0] - 62.0 [51.1,74.0] - 
Missing 4 (1.5%) - 563 (19.0%) - 
Preference weighted 
treatment satisfaction * 57.4 [47.3,66.3] - 59.3 [49.3,68.7] - 
Missing 4 (1.5%) - 577 (19.5%) - 
Social relations * 14.5 [5.5,29.1] - 18.2 [7.3,32.7] - 
Missing 4 (1.5%) - 563 (19.0%) - 
Leisure time restrictions and 
flexibility * 20.0 [10.0,36.7] - 20.0 [6.7,40.0] - 
Missing 4 (1.5%) - 578 (19.5%) - 
Physical complaints * 25.0 [12.5,40.0] - 27.5 [12.5,45.0] - 
Missing 4 (1.5%) - 577 (19.5%) - 
Worries about the future * 56.0 [36.0,76.0] - 60.0 [36.0,80.0] - 
Missing 4 (1.5%) - 579 (19.6%) - 
Daily hassle of functions * 30.0 [15.0,50.0] - 35.0 [20.0,53.3] - 
Missing 4 (1.5%) - 565 (19.1%) - 
     
Figures are median [iqr] or number (%) *Collected only in research centres. 
 
Table 2 Indices of comparability of RCT and cohort 
 
  Indices of generalisability 
Estimator N c-statistic SMD Tipton 
index 
     
Same centres 573 0.62 0.45 0.96 
Full cohort 19238 0.63 0.45 0.95 
Research centres     
  No labs & QoL 2933 0.68 0.63 0.93 
  Including labs & QoL 2242 0.72 0.89 0.91 




































Mean diff (95% CI)
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Complete data for Comparison 1
(N=306)
RCT participants with data (N=267)
Comparison 3 
Attended research centres and 

















Complete data for Comparison 3 
Excluding labs & Qol (N=2669)
Including labs & Qol (N=1989)
RCT participants with data 
Excluding labs & Qol (N=264)
Including labs & Qol (N=253)
Complete data for Comparison 2
(N=18971)
RCT participants with data (N=267)





















Attended DAFNE course 
(N=132)






Attended DAFNE course  
(N=135)
Baseline HbA1c ≥ 58 mmol/mol (7.5%) 
(N=123)
Completed 24 month follow-up 
(N=115)*
Completed 24 month follow-up 
(N=109)**
*  3 participants had no data for comparison 3 (no labs/QoL); 8 participants had no data for comparison 3 (incl. labs/QoL)
** 6 participants had no data for comparison 3 (incl. labs/QoL)
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• RCTs have been criticised for failing to adequately represent the wider population 
• We re-analysed an RCT in type I diabetes mellitus using re-weighting methods to 
better match a large national cohort with regards to disease characteristics, QoL and 
treatment satisfaction 
• Our trial participants differed from those of the cohort, but the revised treatment 
effect was similar to that seen in the original RCT 
What this adds to what is known;  
• Our case study is consistent with claims that RCTs are selective populations, but 
emphasises this does not necessarily invalidate the RCT findings 
What is the implication and what should change now 
• We advocate trialists consider comparisons such as those employed here to explore 
the potential impact of external generalisability  
 
